top of page
The Longevity Edit
The Research
Worth Reading
Every Week
The week's most important research on longevity, health, and performance - carefully selected, clearly explained and delivered to your inbox.
Discover new clinical trials, expert perspectives, and evidence baed insights without spending hours researching journals, headlines, and conflicting health claims.
Complimentary for Bio Precision Aging Members.
One thoughtful edition each week. No noise, no hype, unsubscribe at anytime.
A chemo-free leukemia regimen beats the standard of care, a metabolomic clock that tracks mortality, inflammaging that starts in your 30s, and four other things worth your time this week.
Week of October 26th, 2026 This week's theme is the gap between a headline and the people who were actually measured. A chemotherapy-free leukemia regimen beat the standard of care in a 236-patient phase 3 trial, which is about as clean as clinical evidence gets. A blood metabolome clock built on 18,476 people predicted disease and death, but it is nowhere near a test you can order. Inflammation markers start drifting upward in the 20s and 30s, a Karolinska cohort shows fitne
4 days ago8 min read
Poor sleep and stroke risk, a direct AMPK activator extends lifespan in three species, GLP-1 safety graded honestly and four other things worth your time this week.
Week of October 12th, 2026 This week's theme is the distance between a signal and a recommendation. A senolytic combination reversed liver scarring in a small randomized trial, and a direct AMPK activator stretched lifespan in three invertebrate species, but both come with real asterisks. A Karolinska review sorted the GLP-1 safety conversation into what is established and what is still noise, while a Tufts pilot asked what to do when people stop the drug and the weight retur
Oct 97 min read
Silent heart plaque in 1 in 13 young adults, infections tied to 1 in 8 cancers worldwide, the exact dose of strength training that adds years — and four other things worth your time this week.
Week of October 5th, 2026 This week's data keeps asking the same question from different angles: how much of aging is already happening before you feel a thing, and how much of it still answers to something you control? We open with our favorite update for the week. The largest imaging study yet of how early arterial plaque actually builds, then a global tally of how many cancers trace back to ordinary infections (which one comes in first?), a twist on epigenetic-clock scienc
Oct 59 min read
A joint supplement tied to faster Alzheimer's decline, a fixable nerve-muscle cause of frailty, mammogram over diagnosis fear cut to under 5%, and four other things worth your time this week.
Week of September 28th, 2026 This week keeps circling the same question: when does a modest signal deserve a large response? We open with an uncomfortable finding for anyone who takes glucosamine for joint pain, and pair it with a genuinely hopeful mechanism behind the weak handshake of old age, a nerve-muscle failure point that a drug can partially reverse. Then a dose of the good kind of humility: a huge meta-analysis walking back decades of mammogram overdiagnosis fear, fr
Sep 289 min read
The brain swaps out its own immune cells after 50, four weeks of different food made older adults biologically younger, a blood test for early pancreatic cancer — and four other things this week.
Week of September 21st, 2026. A single-cell map of the human hippocampus shows the brain's original immune cells being replaced by more inflammatory ones between ages 50 and 75. Plus a four-week randomized feeding trial that moved biological age in adults 65 to 75, the astrocyte protein behind APOE4's leaky blood-brain barrier, CREST-2's negative cognitive result, an immune sensor that misreads your own DNA as viral, and a liquid biopsy with 86.8% sensitivity for early pancre
Sep 2111 min read
bottom of page